A Dose Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of ASP2408 Following Single Intravenous Doses in Healthy Subjects

NCT02125435 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

65

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy Subjects
Pharmacokinetics of ASP2408

Interventions

DRUG: ASP2408
DRUG: Placebo

Sponsor

Astellas Pharma Global Development, Inc.